Su-Leng Tan Lee - 13 Aug 2026 Form 4 Insider Report for BioNexus Gene Lab Corp (BGLC)

Reporting relationship: Chief Executive Officer, Director, 10%+ Owner
Issuer ticker: BGLC
Reported as of: 13 Aug 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 14 Aug 2026, 17:20:58 UTC
Prior SEC filing: 31 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ Su-Leng Tan Lee

Key filing fact

Su-Leng Tan Lee filed Form 4 for BioNexus Gene Lab Corp (BGLC) on 14 Aug 2026.

Key facts

This page summarizes Su-Leng Tan Lee's Form 4 filing for BioNexus Gene Lab Corp (BGLC).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 14 Aug 2026, 17:20.

Change

Previous filing in this sequence was filed on 31 Jul 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002141883 Primary reporting owner

Tan Lee Su-Leng

Relationship: Chief Executive Officer, Director, 10%+ Owner
Address: A-28-7, MENARA UOA BANGSAR, NO.5 JALAN BANGSAR UTAMA 1, KUALA LUMPUR, MALAYSIA
Signature: /s/ Su-Leng Tan Lee
Signature date: 13 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BGLC transaction

Common Shares

Award

Transaction value
Shares: +338,709
Change %
Price
Shares after: 338,709
Date: 13 Aug 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents a fully vested Other Stock-Based Award of 338,709 shares of common stock, no par value, granted on August 13, 2026 under the BioNexus Gene Lab Corp. 2025 Equity Incentive Plan. The award was granted for completed services, for no cash consideration and valued for Plan purposes at $1.55 per share (the Nasdaq closing price on August 12, 2026).